Medical disclaimer: This guide is for informational purposes only. CAR-T therapy is a complex, high-risk treatment. Eligibility and suitability must be assessed by a haematologist or oncologist based on full clinical records. BeijingMedAccess is a coordination service only and does not provide clinical opinions or treatment recommendations. Do not delay or discontinue locally recommended treatment while seeking overseas review.
CAR-T cell therapy is one of the most significant advances in blood cancer treatment in recent years. It is also one of the most expensive, most complex, and most frequently misunderstood therapies when it comes to international cost comparisons.
This guide is not a promotion of China-based CAR-T therapy. It is an honest explanation of why US and China cost figures are not directly comparable — and what a patient actually needs to understand before exploring whether a Beijing haematology pathway might be relevant to their case.
If you are in active cancer treatment or facing an urgent treatment decision, do not delay acting on the advice of your current oncologist to seek overseas options. This guide is for patients with time to plan — not patients facing an urgent clinical situation.
In the United States, FDA-approved CAR-T products carry publicly disclosed wholesale acquisition costs (WAC). As of their most recent published pricing:
These figures are drug-only wholesale acquisition costs. They do not include:
Total US treatment costs for CAR-T — including hospital fees, physician fees, and supportive care — are typically estimated at $600,000 to over $1,000,000 per course of treatment at major US academic medical centres. Insurance coverage is the primary variable; uninsured or underinsured patients face extraordinary financial exposure.
Online resources and patient forums frequently cite Chinese CAR-T prices that appear dramatically lower than US figures. These comparisons require careful interpretation.
Key point: US prices refer to the cost of a specific FDA-approved commercial CAR-T product. China-based CAR-T pathways may use commercially approved Chinese products, hospital-developed investigational products, or clinical trial protocols. The products, the regulatory frameworks, the efficacy and safety data available, and what is included in the stated price are all different. These numbers are not directly comparable without knowing exactly what is included in each figure.
Factors that affect any China-based CAR-T cost estimate:
Wholesale acquisition cost for FDA-approved commercial products. Does not include hospital fees, conditioning chemotherapy, inpatient stay, toxicity management, or follow-up. Total treatment cost is substantially higher.
Available estimates for China-based CAR-T pathways vary significantly depending on product, trial vs commercial status, hospitalisation length, complications, and what is included. A reliable estimate requires individual case review and hospital confirmation.
We do not publish a Beijing CAR-T price range. We have deliberately chosen not to state a specific cost figure for Beijing CAR-T pathways in this guide. Available estimates differ substantially depending on product, protocol, and case complexity. Publishing a range would create expectations that may be incorrect for individual patients. The right approach is case-by-case review and direct hospital confirmation.
Beijing Gobroad Hospital (昌平区) and Beijing Gobroad Hospital Boren (丰台区), both part of the Gobroad Healthcare Group, have developed significant clinical CAR-T experience — particularly in relapsed and refractory leukemia, lymphoma, and myeloma. Their published clinical work includes research in Blood, Leukemia, and JCO, and results presented at ASH, EHA, and ASCO.
Key points about Beijing CAR-T experience that are clinically relevant:
This does not mean Beijing CAR-T is right for every patient, or that US FDA-approved products should be bypassed in favour of Chinese protocols. Clinical context matters enormously. What it means is that for some patients — particularly those with relapsed or refractory disease who have exhausted standard options — a specialist review of records by a Beijing haematology team may reveal options worth considering.
When we submit records to a Beijing haematology specialist for review, the output is an assessment of:
A case review cannot tell you whether CAR-T will work for your specific case, what your response rate will be, or whether you will experience serious toxicity. These are clinical questions that no one can answer in advance — in any country.
Why these records matter for CAR-T specifically: Molecular subtype determines target antigen eligibility. Prior treatment history determines whether you are truly refractory or relapsed. Organ function determines whether you can tolerate conditioning chemotherapy and the toxicity management required. Incomplete records cannot be reviewed meaningfully — and submitting an incomplete case may result in an inaccurate assessment of eligibility.
Blood cancer cases — especially CAR-T requests — require more careful handling than many other pathways. Before we submit any haematology case for specialist review, we conduct an initial assessment to confirm:
We will not coordinate a blood cancer case where we believe the patient should be prioritising urgent local treatment, or where the records are insufficient to support a meaningful clinical review.
Start with a free eligibility call. We will tell you honestly whether your case is suitable for specialist review in Beijing — and what records we would need to move forward.
US CAR-T pricing sourced from FDA manufacturer wholesale acquisition cost disclosures for Kymriah (Novartis) and Yescarta (Kite/Gilead). Total treatment cost estimates based on published health economics literature and ICER reports. Beijing clinical experience information based on published peer-reviewed research from Gobroad Healthcare Group hospitals in Blood, Leukemia, JCO, and presentations at ASH, EHA, and ASCO. This guide was last reviewed in May 2026.